PanCAN Scientific Summit 2024

5:30 — 6:30 p.m.

PanCAN Scientific and Medical Advisory Board Kickoff Reception (invite only)

Exeter Room, Mezzanine Level

6:30 — 8:30 p.m.

General Reception

The Square, Lobby Level

Welcome Remarks
Julie Fleshman, JD, MBA, PanCAN President and CEO

Poster Session

2023 Career Development Awards

Immunopeptidomics to Accelerate Immunotherapies in Pancreas Cancer
William Freed-Pastor, MD, PhD, Dana-Farber Cancer Institute
Grant funded in memory of Llewellyn Bixby IV, through a gift made by his family

Use of Supportive Care Medications Among Older Adults with Metastatic Pancreatic Cancer
Arjun Gupta, MD, University of Minnesota Medical School
Grant funded by an anonymous donor

Trajectories of Health Care Contact Days for Veterans with Pancreatic Cancer
Arjun Gupta, MD, University of Minnesota Medical School
Grant funded by an anonymous donor

Mechanisms of Cancer-Nerve Dynamics in Pancreatic Cancer
Peter Wang, PhD, presenting on behalf of William L. Hwang, MD, PhD, Massachusetts General Hospital
Grant funded by Rick Star in Memory of Janet Ranta Star

Role of Stromal Cadherin 11 in Chemotherapy Response in Pancreatic Cancer
Ivana Peran, PhD, Georgetown University’s Lombardi Comprehensive Cancer Center

2023 Fellowship Awards

Glycine availability in the PDAC tumor microenvironment as a driver of chemoresistance
Guillaume Cognet, PhD, University of Chicago
Grant funded by The Francois Wallace Monahan Fund in loving memory of Michael Insel

Understanding mechanisms of response and resistance to RAS-pathway inhibition in pancreatic cancer
Julien Dilly, MS, Dana-Farber Cancer Institute
Grant funded by The Francois Wallace Monahan Fund in loving memory of Michael Insel

Treatment-related Awards

Pelareorep + mFOLFIRINOX +/- atezolizumab for the treatment of 1L mPDAC
Ruimei (Linda) Li, MD, PhD, presenting on behalf of Thomas Heineman, MD, PhD, Oncolytics Biotech, Inc.
Grant supported in memory of Skip Viragh

Proglumide and the Pancreatic Cancer Microenvironment
Jill P. Smith, MD, Georgetown University
Grant extension funded by Kenneth D. Custance and Gladys C. Custance, honoring the memory of Martha ‘Molly’ Reed Woodroofe

Pancreatic Cancer UK Awards

Unravelling fibroinflammatory and immune signatures for pancreatic cancer early detection
Pilar Acedo, PhD, University College London

Treatment of pancreatic tumours with therapeutic ultrasound
Petros Mouratidis, PhD, The Institute of Cancer Research, London

Transcription factor switching drives progression of the classical subtype of pancreatic cancer
Shalini Rao, PhD, Cancer Research UK, University of Cambridge

Identifying and Characterizing Cancer Initiating Cells Driving PanIN Progression and Tumour Development in Pancreatic Cancer
Beatriz Salvador, PhD, Cardiff University

Identification of therapeutic vulnerabilities in the subset of pancreatic ductal adenocarcinoma (PDAC) with homologous recombination deficiency
Mathias Tesson, PhD, Cancer Research UK, Scotland Institute

7:30 — 8:20 a.m.

Breakfast

The Square, Lobby Level

8:30 a.m. — 3:15 p.m.

Scientific Sessions

Avenue 34, Lobby Level

8:30 — 8:35 a.m.

Welcome

Eileen O’Reilly, MD, Memorial Sloan Kettering Cancer Center
Chair, PanCAN Scientific and Medical Advisory Board

8:35 — 9 a.m.

PanCAN: 25 Years + Counting – Pioneering the Next Breakthroughs

Julie Fleshman, JD, MBA

9 — 9:30 a.m.

Early Detection

Session Facilitator: Lynn Matrisian, PhD, MBA, PanCAN Chief Science Officer

Updates on the Early Detection Initiative (EDI), the cohort (REGARD), and the case-control (PANDORA) studies identifying cases of pancreatic cancer in individuals with new-onset diabetes (NOD) and new-onset prediabetes (NOPD)
Suresh Chari, MD, MD Anderson Cancer Center
2022 Catalyst Award funded by The Henry and Marilyn Taub Foundation honoring the memory of Shirley Sadoff

9:30 — 10 a.m.

PanCAN's SPARK – Partnering with PanCAN's Health Data

Session Facilitator: Sudheer Doss, PhD, PanCAN Chief Business Officer

Computational Histology AI as a predictive biomarker for first line treatment selection in PDA
Eric A. Collisson, MD, Fred Hutchinson Cancer Center

Genialis™ krasID: Biology-Driven Machine Learning to Personalize KRAS Inhibitor Therapy in Pancreatic Cancer and Beyond
Joshua Wheeler, MD, PhD, Genialis, Inc.

10 — 10:40 a.m.

2022 Career Development Awards, part 1

Session Facilitators: Julie Fleshman, JD, MBA, Eileen O’Reilly, MD

10 — 10:20 a.m.

The Role of PP2A in Regulating Pancreatic Cancer Macropinocytosis
Brittany Allen-Petersen, PhD, Purdue University
Grant funded by The Rockhammer Charitable Fund

10:20 — 10:40 a.m.

A Novel Mechanism of MDSC-mediated Stromal and T-cell Dysregulation in PDAC
Jashodeep Datta, MD, University of Miami
Grant funded by an anonymous donor

10:40 — 10:55 a.m.

Break

11 a.m. — 12:40 p.m.

2022 Career Development Awards, part 2

Session Facilitators: Julie Fleshman, JD, MBA, Eileen O’Reilly, MD

11 — 11:20 a.m.

KRAS G12R Metabolic Reprogramming Alters Therapeutic Sensitivity
G. Aaron Hobbs, PhD, Medical University of South Carolina Hollings Cancer Center
Grant funded in memory of Skip Viragh

11:20 — 11:40 a.m.

Immunobiological Factors Associated with Pancreatic Cancer Disparities
Janielle Maynard, PhD, Johns Hopkins University School of Medicine
Grant funded by the Chrysalis Fund at the Ventura County Community Foundation

11:40 — noon

Neuronal Checkpoint Signaling in Pancreas Cancer Pain
Jami Saloman, PhD, University of Pittsburgh
Grant funded in memory of Skip Viragh

Noon — 12:20 p.m.

Microbial TMAO: Boosting Pancreatic Cancer Treatment
Rahul Shinde, PhD, Ellen and Ronald Caplan Cancer Center, The Wistar Institute
Grant funded by an anonymous donor

12:20 — 12:40 p.m.

Remote Nutrition Monitoring for Metastatic Pancreatic Cancer Patients
Kea Turner, PhD, Moffitt Cancer Center
Grant funded by an anonymous donor

12:40 — 1:30 p.m.

Lunch

The Square, Lobby Level

1:40 — 3:15 p.m.

Pancreatic Cancer Treatment Approaches

1:40 — 2 p.m.

PanCAN Precision Promise® Update
Anna Berkenblit, MD, MMSc, PanCAN Chief Scientific & Medical Officer

2 — 2:20 p.m.

Phase 1/2 Trial of Avutometinib + Defactinib and GEM + Nab-P in Metastatic PDAC
Sheena Clift, PhD, presenting on behalf of John Hayslip, MD, Verastem Oncology
2022 Therapeutic Accelerator Award supported by 1440 Foundation, the Gail V. Coleman-Kenneth M. Bruntel Research Fund, Lyda Hill Philanthropies, The Bern Schwartz Family Foundation, and in memory of Skip Viragh

2:20 — 2:45 p.m.

2022 Therapeutic Accelerator Collaborative Awards Lightning Talks

Session Facilitator: Lynn Matrisian, PhD, MBA

Preclinical and Translational Studies to Inform the Development of Strategies Targeting the KRAS Pathway
Gregory L. Beatty, MD, PhD, Perelman School of Medicine at the University of Pennsylvania
Grant funded in memory of Llewellyn Bixby IV, through a gift made by his family

Determine How FAK/MEK Inhibition Alters Tumor-Microenvironment Interactions and the Immune Response
David DeNardo, PhD, Washington University in St. Louis

Tumor Microenvironment Determinants of Resistance to KRAS/FAK Inhibition
Marina Pasca di Magliano, PhD, University of Michigan
Grant funded by The Henry and Marilyn Taub Foundation honoring the memory of Shirley Sadoff

Determination of Novel RAF/MEK and/or FAK Inhibitor Combinations in KRAS-mutant PDAC
Kirsten Bryant, PhD, and Channing Der, PhD, University of North Carolina at Chapel Hill
Grant funded in memory of Llewellyn Bixby IV, through a gift made by his family

Identify Genetic and Phenotypic Mechanisms of Response or Resistance to RAF/MEKi +/- FAKi in Pancreatic Cancer
Andrew Aguirre, MD, PhD, Dana-Farber Cancer Institute
Grant funded by The Henry and Marilyn Taub Foundation honoring the memory of Shirley Sadoff

2:45 — 3:05 p.m.

2022 Therapeutic Accelerator Collaborative Awards Panel Discussion

3:05 — 3:10 p.m.

Closing Remarks

Eileen O’Reilly, MD

3:15 — 4 p.m.

Coffee and Networking

The Loft, Lobby Level